Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Jul 23, 2014
Insider Transaction Report
Form 4
Kuno Sachiko
Director10% Owner
Transactions
- Sale
Class A Common Stock
2014-07-22$6.25/sh−2,500$15,635→ 22,803,202 total(indirect: By LLC) - Sale
Class A Common Stock
2014-07-21$6.25/sh−100$625→ 22,805,702 total(indirect: By LLC) - Sale
Class A Common Stock
2014-07-23$6.32/sh−3,245$20,507→ 22,799,957 total(indirect: By LLC)
Holdings
- 353,530(indirect: By Spouse)
Class A Common Stock
- 60,357
Class A Common Stock
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on September 11, 2013.
- [F2]S&R Technology Holdings, LLC is wholly owned by Dr. Kuno and her husband. Dr. Kuno disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.35, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Dr. Kuno disclaims beneficial ownership of the reported securities.